Discontinuing Beta-Blockers After MI Reasonable in some Patients

Why It Matters

The results could reshape long‑term post‑MI medication strategies, reducing pill burden and potential side effects for patients who lack high‑risk features.

Key Takeaways

• Discontinuation non‑inferior to continuation after one year post‑MI
• Study enrolled 2,540 low‑risk patients, median 3.1‑year follow‑up
• Stroke rates lower in discontinuation group; other outcomes similar
• Findings apply to patients without heart failure or reduced EF
• Shared decision‑making recommended before stopping beta‑blockers

Pulse Analysis

Beta‑blockers have been a cornerstone of post‑myocardial infarction therapy for decades, primarily because early trials demonstrated mortality benefits in patients with reduced left ventricular ejection fraction or overt heart failure. Over time, guideline committees have broadened recommendations to include all post‑MI patients, despite limited data supporting long‑term use in those with preserved cardiac function. This practice has contributed to polypharmacy, especially as modern MI survivors also manage dual antiplatelet agents, high‑intensity statins, and often antihypertensives, increasing the risk of non‑adherence and adverse drug interactions.

The SMART‑DECISION trial, published in the New England Journal of Medicine, fills a critical evidence gap by randomizing over 2,500 low‑risk patients to either continue or discontinue beta‑blockers a full year after their infarction. With a median follow‑up exceeding three years, the study demonstrated non‑inferiority for the primary composite endpoint and even a modest reduction in stroke among those who stopped therapy. These outcomes align with the earlier ABYSS trial, which failed to prove superiority of interruption, but SMART‑DECISION is the first to meet rigorous non‑inferiority criteria, lending greater confidence to clinicians contemplating de‑escalation in similar populations.

For practitioners, the practical takeaway is to reassess beta‑blocker necessity during the one‑year post‑MI visit, especially when patients exhibit normal ejection fraction, no heart‑failure symptoms, and no other indications such as arrhythmia control. A shared‑decision‑making conversation can weigh the modest stroke benefit against potential heart‑rate‑related anxiety and the overall medication load. While the data are reassuring for low‑risk cohorts, they do not extend to early post‑MI phases or patients with comorbidities, underscoring the need for individualized care plans and further research into optimal timing for safe discontinuation.